SAGE Clinical Trial Fails

Sage Therapeutics announced disappointing results on its late-stage clinical trial of a brexanolone treament for a seizure disorder called super-refractory status epilepticus (SRSE). Right now there is no U.S. drug approved for the condition.

Sonal caught the news at 6:15 am with a level 2 alert before the stock price fell from $88.22 to $74.65.

 

Over the next three trading sessions, Sonal subscribers witnessed the familiar pullback and trend pattern. During the first day, the price surged back up to $76.39. The price continued to fade over the next two trading sessions before closing at $65.69.

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!